Accuracy of real-time magnetic resonance imaging-transrectal ultrasound fusion image-guided transperineal target biopsy with needle tracking with a mechanical position-encoded stepper in detecting significant prostate cancer in biopsy-na € ıve men Objective: To evaluate the accuracy of real-time elastic fusion image-guided transperineal prostate biopsy with needle tracking involving a mechanical positionencoded stepper in detecting clinically significant prostate cancer for biopsy-na€ ıve men.
Introduction mpMRI is increasingly used to diagnose clinically significant PCa, because of its growing availability, and advances that combine anatomical and functional data. 1, 2 In the 2014 European Association of Urology guideline, mpMRI was considered to be a particularly accurate method of detecting anterior tumors that are usually missed by systematic biopsy and therefore trigger a repeat (targeted) biopsy. 3 As the cost-effectiveness of mpMRI as a triage test before the initial biopsy has not been assessed, less evidence exists for its use in primary biopsies than repeat biopsies. 3 However, the efficacy of mpMRI for detecting PCa has been widely verified. To standardize evaluation and reporting of mpMRI findings for the prostate, the ESUR published guidelines, termed the PI-RADS. 4 In a diagnostic meta-analysis, the sensitivity and specificity for pooled studies were 0.78 (95% CI 0.70-0.84) and 0.79 (96% CI 0.68-0.86), respectively. 5 Junker et al. reported the AUC for cancer detection with PI-RADS in the PZ and TZ were 0.97 and 0.60, respectively. 6 Based on these results, PI-RADS is regarded as an accurate method of diagnosing PCa.
Methods that involve MRI-navigated prostate biopsy, visual registration [7] [8] [9] and software registration have been used. In visual registration, the TRUS operator views lesions that were suspicious on MRI, estimates their location within the prostate, and then attempts to identify and biopsy these locations using real-time TRUS. 10 Delongchamps et al. reported that the cancer detection rate by visual registration was similar to that with systematic biopsies (P = 0.66). 11 Wysock et al. reported that fusion biopsies provided more informative non-benign histology than visual registration (P = 0.0104). 12 In addition, the disadvantages of visual registration lie in human error when attempting to mentally fuse MRI with TRUS while targeting cancers that are often <10 mm in diameter, and the inability to track the locations for each biopsy. 13 To minimize human error and maximize accuracy, several software-based fusion devices are used for targeted biopsy, and have similar steps, but differ by type of image registration (rigid vs elastic), method of needle tracking (electromagnetic tracking vs position-encoded joints tracking vs imagebased software tracking) and route of biopsy (transperineal vs transrectal). Although the international working group recommended START for the prostate, the present biopsy method had not followed the START recommendation for significant cancer detection in biopsy-na€ ıve men. 9 The present study evaluated the accuracy of real-time elastic fusion imageguided transperineal prostate biopsies with needle tracking based on a mechanical position-encoded stepper.
Methods Patients
We prospectively recruited all biopsy-na€ ıve patients with serum PSA levels of 4.0-20 ng/mL who were suspected of having PCa through mpMRI scans taken from October 2014 to August 2016. This study was approved by our institutional review board.
Image analysis
Details of the MRI examination were described in an earlier study.
14 All mpMRI images, including those using T2WI, DWI and ADC mapping, were reviewed by two experienced radiologists who were blinded to the patients' other clinical information. The radiologists each had over 10 years' experience and over 100 diagnostic experiences in prostate 4, 15 By combining scores for of T2, DWI (ADC) and DCE, lesions received PI-RADS scores: 5 or 6, PI-RADS 2; 7-9, PI-RADS 3; 10-12, PI-RADS 4; and 13-15, PI-RADS 5. The location of each area was determined by dividing the prostate into 27 regions. 16 MRIs were imported into the biopsy fusion system. Segmentation into a 2-D mpMRI was carried out on the workstation to create a 3-D model of the MRI, and then fused to the realtime TRUS.
Biopsy protocol
Patients each received a cleaning enema and antibiotics before the biopsy. TRUS with power Doppler was carried out using a Prosound a7 (Hitachi Aloka Medical, Tokyo, Japan) equipped with a UST-678 transrectal composite probe, in the lithotomy position under spinal anesthesia. Using BioJet version 2.0 (D&K Technologies GmbH, Barum, Germany), MRI was fused to the real-time TRUS by means of elastic fusion. During the procedure, the real-time fusion image was continuously available (Fig. 1a) , and the biopsy template coordinates were shown on the computer monitor when the operator selected a given biopsy target. For small targets, the template moved slightly without movement of the real-time image to achieve successful punctures in the system. The biopsy process started with targeted biopsies, and then 12-core systematic biopsies were carried out transperineally. In target biopsies, at least two cores were taken for each lesion. Higher GS and/or longer cancer core lengths were regarded as pathological findings in targeted lesions. Immediately after each biopsy, spatial orbits of the needle punctures were recorded in the 2-D TRUS image, and in the 3-D model reconstructed from the MRI scan (Fig. 1b) . An 18-G automatic biopsy gun with a 22-mm specimen size (Bard Magnum; Bard Medical, Covington, KY, USA) was used to obtain the biopsy cores.
Pathological analysis
All biopsies were examined by two senior pathologists, who reviewed each other's results. Clinically significant cancer was defined as having at least one core with a GS of 3 + 4, or GS 6 with a maximum cancer core length >4 mm, and insignificant cancer was defined as having core with ≤GS 6 with a maximum cancer core length ≤4 mm. 17 Pathological results of systematic and targeted biopsies were compared. Preoperatively diagnosed PCa locations were compared with pathological findings from step-sectioned whole-mount specimens in all patients who had radical prostatectomies after diagnosis by the biopsies in the present study. 16 Tumor volume was calculated as previously described.
18 
Statistical analysis
All statistical analyses were carried out using IBM SPSS Statistics version 19 (IBM, Armonk, NY, USA). Cancer detection rates, and comparisons of pathological findings between systematic and targeted core biopsies were analyzed using the McNemar test. Comparison of detection rates for clinically significant cancers in targeted-lesion biopsies of lesions ≤10 mm and >10 mm, scored using the PI-RADS classification, were analyzed by the Mann-Whitney U-test.
We evaluated PI-RADS scores to detect PCa using ROC analyses.
Results
We included 250 patients in the present study. The detection rate for cancers with GS ≥3 + 4 = 7 was 45% (112/250). Cancer detection rates significantly differed between target (44%, 110/250) and systematic (15%, 37/250) biopsies (P < 0.001). Pathological findings from systematic and targeted prostate biopsy cores in this series are detailed in Table 1 . In the targeted biopsy cores, cancer-detection rates (P < 0.001), biopsy-proven significant cancer detection rates (P < 0.001), median positive core length (P < 0.001), median positive core percentage (P < 0.001) and median GS (P < 0.001) were significantly higher than for systematic biopsy cores. Cancer detection rates for targeted lesions scored using the PI-RADS classification were PI-RADS 2: 2.7%; PI-RADS 3: 19%; PI-RADS 4: 54%; and PI-RADS 5: 83%; and for biopsy-proven, clinically significant cancers were PI-RADS 2: 0%; PI-RADS 3: 6.8%; PI-RADS 4: 49%; and PI-RADS 5: 80% ( Table 2 ). The sensitivity, specificity, positive predictive value and negative predictive value of the PI-RADS classification score 5 for the detection of biopsy-proven significant cancer were 67%, 89%, 55%, and 93% in TZ, and 44%, 93%, 90%, and 54% in PZ, respectively. Detection rates for biopsy-proven clinically significant cancers among targeted lesions ≤10 mm and >10 mm were similar for those with PI-RADS scores of 4 (50% vs 51%; P = 0.707) and 5 (75% vs 68%; P = 0.386). In each TZ and PZ, biopsy-proven significant cancer detection rates for targeted lesions were also similar for tumors ≤10 mm and >10 mm. ROC curves using the PI-RADS classification showed AUCs that were significantly greater than non-discrimination for all targeted lesions (AUC 0.835, 95% CI 0.792-0.879; P < 0.0001), lesions ≤10 mm (AUC 0.855, 95% CI 0.805-0.905; P < 0.0001) and >10 mm (AUC 0.835, 95% CI 0.844-0.903; P < 0.0001; Fig. 2 ).
Cancer detection rates for targeted lesions scored using the PI-RADS classification in the whole-mount specimen (n = 30) were PI-RADS 2: 0%; PI-RADS 3: 38%; PI-RADS 4: 85%; and PI-RADS 5: 89%; and for biopsy-proven significant cancers in targeted lesions were PI-RADS 2: 0%; PI-RADS 3: 13%; PI-RADS 4: 72%; and PI-RADS 5: 84% (Table 3 ). Cancer detection rates for biopsy-proven significant cancers in targeted lesions ≤10 mm and >10 mm were similar at PI-RADS scores of 4 (70% vs 75%; P = 0.872) and 5 (89% vs 89%; P = 0.780). In each TZ and PZ, detection rates for significant cancers in targeted lesions ≤10 mm and >10 mm were also similar.
In the 30 patients from whom whole-mount specimens were taken, we found 43 clinically significant cancers, of which 41 (95%) had been detected by both the targeted and systematic biopsies. Of the 41 cancers detected by targeted biopsy, 34 (79%) were clinically significant and seven (16%) were insignificant cancers. The median major diameter of significant cancers in the whole-gland specimens was 12 (range 5-28) mm; lesions ≤10 mm represented 59% of the significant cancers (n = 24). Of the significant cancers ≤10 mm (n = 24) in whole-mount specimens, 96% (n = 23) were correctly diagnosed by biopsy. Targeted biopsy cores showed significantly greater values than systematic biopsy cores for overall cancer detection rate (P < 0.001), median positive core length (P < 0.001), median positive core percentage (P < 0.0001) and median GS (P < 0.001; Table 4 ). GSs and locations of biopsy-proven significant cancers corresponded to histopathological findings for the whole-mount specimens.
Discussion
Recently, several software-based MRI-TRUS fusion imageguided prostate biopsy devices have become commercially available for targeted biopsies. They differ by type of image registration (rigid vs elastic) and needle tracking method (electromagnetic tracking vs mechanical position encoders vs image-based software tracking). BioJet version 2.0 induces elastic registration using the needle tracking method with a mechanical position-encoded stepper; elastic registration matches the corresponding point landmarks, and aligns them with the surface contours of the prostate. Using a positionencoded mechanical stepper, location of the TRUS probe in 3-D space is tracked by direct attachment to the mechanical stepper. Angle sensors in the mechanical stepper encode and automatically relay the position of the probe and needle in 3-D space to the computer. Although the ultrasound probe suppresses in-out and rotational movements, the tracking helps reduce instability from TRUS movement during the procedure. The present results show that this targeted biopsy method accurately detects clinically significant cancers in lesions highly suspected of cancer. Using a similar device from the BiopSee (Pi Medical, Athens, Greece), Radtke et al.
reported that the transperineal MRI-TRUS fusion image targeted biopsy and combined targeted + 24-core systematic biopsies detected 79% and 97%, respectively, of significant cancers in analysis of whole-mount specimens. 19 The Artemis system (Eigen, Grass Valley, CA, USA), which uses elastic fusion and position-encoded joints in smart robotic arms, has been used for transrectal targeted biopsy. Wysock et al. reported that cancer core detection rates in targeted biopsies (n = 9.4%) were significantly higher than in 12-core systematic biopsy cores (5.7%; P < 0.05). 12 Median lesion core lengths (3.75 mm vs 2.86 mm; P < 0.05) and percentages of cancer core length (34.25% vs 26.12%; P < 0.05) in targeted biopsies were significantly higher than in 12-core systematic biopsies. 12 The UroNav system (Invivo, Gainesville, FL, USA) uses elastic fusion and electromagnetic needle tracking. Siddiqui et al. reported that transrectal targeted biopsies using the UroNav (n = 461) diagnosed 30% more PCas with GS ≥4 + 3 than did 12-core template systematic biopsies (n = 469; 173 vs 122 cases; P < 0.001). 20 Oberlin et al. reported that the cancer detection rate for transrectal targeted biopsy using the UroNav system was significantly higher at 48.1% (39/81 patients) than for transrectal biopsy with visual registration at 34.6% (52/150 patients; P = 0.04) or 12-core transrectal systematic biopsy at 32% (32/100 patients; P = 0.03). 21 The Urostation system (Koelis, Meylan, France) uses elastic fusion and 3-D TRUS image needle tracking. 22 Mozer et al. reported that targeted biopsies with the Urostation had significantly higher overall cancer detection rates (31% vs 7.5%; P < 0.001) and detection rates for clinically significant cancers (43% vs 37%; P = 0.03) than did 12-core systematic biopsy in 152 patients with PSA levels <10 ng/ mL. 23 In addition, the length of positive cores in targeted biopsies (median 8 mm) was significantly higher than in systematic biopsies (median 4 mm; P < 0.0001; n = 152). 23 In the present analysis of whole-mount specimens, targeted and combined targeted + systematic biopsies detected 79% and 95%, respectively, of significant cancers. As significant cancer detection by mpMRI is reportedly 85-90%, systematic biopsies would help detect significant cancers. 19, 24 Recabal et al. reported the detection rate of higher grade cancers (GS ≥7) for systematic biopsy was 11% without ROI on mpMRI, but was 47% for MRI-targeted + systematic biopsy with ROI on mpMRI. However, they caution against using mpMRI alone for risk stratification, because they identified a small but clinically significant number of Gleason ≥7 cancers with no ROI identified on mpMRI. 25 Borkowetz et al. reported that GS concordance rates between prostate biopsies and radical prostatectomy specimens by method were targeted biopsies: 63%; systematic: 54%; and combined targeted + systematic: 75%; they concluded that the combined approach best predicts final tumor grading. 26 Pepe et al. reported that 25% of patients were reclassified by systematic biopsies based on upgraded GS ≥7. 27 Along with previous reports, the present results show that combined targeted + systematic biopsies are currently the most accurate method to detect clinically significant PCa. Interestingly, we found targeted biopsy cores to have significantly higher GS than systematic cores, which we believe is because targeted biopsies take tissue from the centers of lesions, whereas systematic biopsies take samples throughout the gland.
The present study had several limitations. First, comparisons between biopsy results and whole-gland specimens were restricted by the small number of whole-gland specimens. Therefore, although locations and pathological grades of clinically significant cancers corresponded with the targeted biopsy results, a larger study is required to verify our results. Second, investigators were not blinded to MRI lesions during the systematic biopsy. However, the systematic biopsy was carried out independently from the MRI. Third, patients with serum PSA levels >20 ng/mL were excluded, and 12-core systematic biopsies were carried out for all patients regardless of prostate volume. The PSA criterion and number of biopsy cores would affect cancer detection through systematic biopsy. Fourth, this was a single-institution study, and patients were not randomized to facilitate comparison of biopsy techniques. Therefore, a multi-institutional randomized study is required to compare the effectiveness of biopsy methods. Fifth, we have no data to compare the present biopsy methods with visual registration, and therefore, cannot conclude that targeted biopsies are superior to visual registration.
In conclusion, the targeted biopsy is superior to the systematic biopsy in detecting biopsy-proven, clinically significant cancer, at present. However, systematic biopsies have an important role in diagnosing this disease. Median Gleason score of biopsies 7 (range 6-9) 6 (range 6-7) <0.001
